Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ProStrakan Secures Offer From Japan's Kyowa Hakko, But Analysts Say Too Low

This article was originally published in PharmAsia News

Executive Summary

Three months after putting itself up for sale, U.K.-based specialty pharma firm ProStrakan Group PLC on Feb. 21 announced a cash offer from Japan's Kyowa Hakko Kirin Co. Ltd. The 130 pence-per-share deal values the company at about £292 million ($475 million)

You may also be interested in...

Abstral Approval May Fetch ProStrakan The Valuation It's After

A second U.S. product approval in two weeks, plus a partner-driven re-financing, means the price of ProStrakan just went up.

ProStrakan In Buyers' Sights After Setbacks

The specialty pharma company is 'evaluating interest' from buyers after delays to key drugs.

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts